Italy· 041527019
PYLERA*120 cps 140 mg + 125 mg + 125 mg flacone
A medicinal product containing bismuto subcitrato potassio/metronidazolo/tetraciclina cloridrato, registered in Italy by LAB.JUVISE' PHARMACEUTICALS, on the national reimbursement list.
Checked against the register on
Informational only — not a medical device.
The record
At a glance
- Active substance
- Bismuto subcitrato potassio/metronidazolo/tetraciclina cloridrato
- Manufacturer
- LAB.JUVISE' PHARMACEUTICALS
- Country
- Italy (IT)
- ATC code
- —
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic041527019PYLERA*120 cps 140 mg + 125 mg + 125 mg flaconeEUR 67.41
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5ae97da9-9a39-4bba-bd8f-6090027923e0 GET /v1/drugs/5ae97da9-9a39-4bba-bd8f-6090027923e0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 67.41,
"source": "aifa",
"currency": "EUR",
"strength": "BISMUTO SUBCITRATO POTASSIO+METRONIDAZOLO+TETRACICLINA CLORIDRATO 140+125+125MG 120 UNITA' USO ORALE",
"substance": "Bismuto subcitrato potassio/metronidazolo/tetraciclina cloridrato",
"equivalence_group": "GTH",
"transparency_flag": null
}See everything about bismuto subcitrato potassio/metronidazolo/tetraciclina cloridrato.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.